Literature DB >> 3580341

Treatment of ptosis in chronic progressive external ophthalmoplegia.

C M Lane, J R Collin.   

Abstract

Seventeen patients with ptosis as a feature of chronic progressive external ophthalmoplegia were managed in accordance with a new protocol. An anterior approach levator advancement was performed on seven patients (13 lids) with more than 4 mm of levator function and a brow suspension procedure on eight patients (14 lids) with minimal levator function, in whom the frontalis muscle was relatively spared. Ptosis props were prescribed for two patients with a very weak orbicularis and poor lid closure. Six patients required long term lubricants, and one developed a postoperative corneal abscess associated with a poor Bell's phenomenon. Satisfactory elevation of the lids was achieved in 16 patients (25 lids).

Entities:  

Mesh:

Year:  1987        PMID: 3580341      PMCID: PMC1041145          DOI: 10.1136/bjo.71.4.290

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  14 in total

1.  MYASTHENIA GRAVIS: A REVIEW OF THE DISEASE AND A DESCRIPTION OF LID TWITCH AS A CHARACTERISTIC SIGN.

Authors:  D G COGAN
Journal:  Arch Ophthalmol       Date:  1965-08

2.  Retinitis pigmentosa, external ophthalmophegia, and complete heart block: unusual syndrome with histologic study in one of two cases.

Authors:  T P KEARNS; G P SAYRE
Journal:  AMA Arch Ophthalmol       Date:  1958-08

3.  Repair of ptosis using frontalis muscle and fascia lata.

Authors:  J S CRAWFORD
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1956 Sep-Oct

4.  Repair of ptosis using frontalis muscle and fascia lata: a 20-year review.

Authors:  J S Crawford
Journal:  Ophthalmic Surg       Date:  1977-08

5.  Brow suspension in the management of ptosis: an analysis of over 100 cases.

Authors:  E G Kemp; C R James; J R Collin
Journal:  Trans Ophthalmol Soc U K       Date:  1986

6.  Atypical muscle mitochondria in oculoskeletal myopathy.

Authors:  J A Morgan-Hughes; W G Mair
Journal:  Brain       Date:  1973-06       Impact factor: 13.501

7.  Ophthalmoplegia plus. The neurodegenerative disorders associated with progressive external ophthalmoplegia.

Authors:  D A Drachman
Journal:  Arch Neurol       Date:  1968-06

8.  The surgical treatment of blepharoptosis: a quantitative approach.

Authors:  C Beard
Journal:  Trans Am Ophthalmol Soc       Date:  1966

9.  Ocular changes in myotonic dystrophy.

Authors:  H M Burian; C A Burns
Journal:  Am J Ophthalmol       Date:  1967-01       Impact factor: 5.258

10.  Neuromyopathic ptosis: a new surgical approach.

Authors:  R L Anderson; R S Dixon
Journal:  Arch Ophthalmol       Date:  1979-06
View more
  6 in total

1.  3D printing for low cost, rapid prototyping of eyelid crutches.

Authors:  Michael G Sun; Duangmontree Rojdamrongratana; Mark I Rosenblatt; Vinay K Aakalu; Charles Q Yu
Journal:  Orbit       Date:  2018-03-02

2.  Treatment of Eyelid Ptosis due to Kearns-Sayre Syndrome Using Frontalis Suspension.

Authors:  Laurenz Weitgasser; Gottfried Wechselberger; Florian Ensat; Rene Kaplan; Michaela Hladik
Journal:  Arch Plast Surg       Date:  2015-03-16

3.  Bilateral lid/brow elevation procedure for severe ptosis in Kearns-Sayre syndrome, a mitochondrial cytopathy.

Authors:  Roberto Sebastiá; Ester Fallico; Matteo Fallico; Eduardo Fortuna; Sergio Lessa; Guilherme Herzog Neto
Journal:  Clin Ophthalmol       Date:  2014-12-22

4.  Levator resection in the management of myopathic ptosis.

Authors:  Ibrahim Bulent Buttanri; Didem Serin
Journal:  Korean J Ophthalmol       Date:  2014-11-19

5.  Efficacy of frontalis suspension with silicone rods in ptosis patients with poor Bell's phenomenon.

Authors:  Khyati P Shah; Bipasha Mukherjee
Journal:  Taiwan J Ophthalmol       Date:  2017 Jul-Sep

6.  Surgical Treatment of Severe Ptosis by Modified Brow Suspension Technique.

Authors:  Ali Adawal Ali; Abdulhameed Abdul Majeed Hassan; Marwan Salah Salman
Journal:  Plast Surg (Oakv)       Date:  2019-10-24       Impact factor: 0.947

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.